Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2007

View Archived Issues

Six-month study shows prevention of depressive relapses with agomelatine

Recent Atir patent discloses novel agents for male sexual dysfunction

Novel antiinfectious agent reported in recent patent literature

Recent patents report novel therapeutic agents for neurological disorders

AST-120 effective in pouchitis pilot study

MBP-8298 safe in phase III MAESTRO-01 multiple sclerosis trial

Minocycline beneficial in patients with acute stroke

Aida identifies potential targets in phase II trial with Rh-Apo2L

Dynavax starts environmental exposure chamber study of Tolamba

DepoDur modified-release injection approved in Australia

Aripiprazole ineffective in treating methamphetamine dependence

Avant and Celldex sign merger and provide update on future activity

Raptor establishes subsidiary and acquires first clinical-stage product

Kyowa Hakko and Kirin Pharma to merge

Can-Fite's CF-102 promotes liver tissue regeneration following partial hepatectomy

FDA and EMEA grant orphan drug status to SQ-109 for tuberculosis

Summit initiates phase I clinical trial of SMT-D002 for seborrhea in PD

Mutations in PEX2 identified as the cause of Zellweger syndrome

Dendreon completes enrollment in phase III trial of Provenge for advanced prostate cancer

Lu-AA-24530 enters phase II for mood and anxiety disorders

Oncolytics Biotech receives U.K. approval to evaluate Reolysin

Morria Biopharmaceuticals advances MRX-4 to phase I for allergic rhinitis

PAION commences phase I trial of Solulin

APITD1, a candidate tumor suppressor gene in neuroblastoma

Inhibitex begins phase I study of FV-100 for shingles

FDA accepts Wyeth's sNDA for Tygacil in CAP

FDA grants fast track designation to Phamasset's R-7128 in chronic HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...